Your Subscription

We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.





Login
Twitter LinkedIn




Login
  • Home
  • About
  • Updates
  • Awards
  • Contact
  • Directory
  • OnDemand
  • Partners
  • Testimonials
Forward Share Print
Smart & Biggar

National pharmacare update: publication of advisory council's final report

Newsletters

17 July 2019

Healthcare & Life Sciences Canada


On 12 June 2019 the minister of health published the final report (A Prescription for Canada: Achieving Pharmacare for All) from the Advisory Council on the Implementation of National Pharmacare.(1) The council has recommended that Canada should implement universal, single-payer, public pharmacare by enacting new legislation and proceed in a stepwise approach to implementation. The 2019 Federal Budget announced funding for some of the steps, including the formation of an arms-length national drug agency (for further details please see "Pharmacare advisory council delivers initial recommendations").

The final report outlines the following timeline for implementation:

  • By 1 January 2022 the new agency should be responsible for the creation of a national formulary, listing essential medicines covering about half of all prescriptions and most major conditions.
  • By 2027, this initial formulary should be expanded to a fully comprehensive formulary.
  • By 1 January 2022 the report calls for the establishment of a strategy for expensive drugs for rare diseases.

The council recommends the enactment of new legislation that is separate and distinct from the Health Act. The legislation would outline how governments will work together and share costs, list federal responsibilities and include steps for opting in by provincial and territorial governments.

In a statement, the minister of health detailed that the government "will carefully review the Council's final report and its recommendations" over the coming months. However, Parliament has adjourned until 16 September 2019 and implementation of the council's recommendations may depend on what happens in the federal election, which is scheduled for 21 October 2019.

For further information on this topic please contact Urszula Wojtyra at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (uawojtyra@smart-biggar.ca). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.

Endnotes

(1) For further information see "News release" and "Backgrounder".

The materials contained on this website are for general information purposes only and are subject to the disclaimer.

ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.

Forward Share Print

Author

Urszula Wojtyra

Urszula Wojtyra

Register now for your free newsletter

View recent newsletter

More from this firm

  • Federal Court finds silodosin formulation patent valid but not infringed
  • Innovators challenge final PMPRB Guidelines in new Federal Court application
  • Federal Court orders minister of health to issue NOC to Fresenius Kabi for biosimilar
  • Few significant changes made in final PMPRB guidelines
  • CADTH harmonises drug reimbursement review process

More articles

  • Home
  • About
  • Updates
  • Awards
  • Contact
  • My account
  • Directory
  • OnDemand
  • Partners
  • Testimonials
  • Follow on Twitter
  • Follow on LinkedIn
  • Disclaimer
  • Privacy policy
  • GDPR Compliance
  • Terms
  • Cookie policy
Online Media Partners
Inter-Pacific Bar Association (IPBA) International Bar Association (IBA) European Company Lawyers Association (ECLA) Association of Corporate Counsel (ACC) American Bar Association Section of International Law (ABA)

© 1997-2021 Law Business Research

You need to be logged in to make a comment. Log in here.
Many thanks. Your comment has been sent.

Your details



Your comment or question *